Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Recent Patents on Anti-Cancer Drug Discovery

• Publication date

  2016-03-31

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/1574892811666160229121544PMID 26924736
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells.

  2015cited by this paper
• Getting TRAIL back on track for cancer therapy

  2014cited by this paper
• Death receptor agonist therapies for cancer, which is the right TRAIL?

  2014cited by this paper
• Death receptors as targets in cancer

  2013cited by this paper
• Liposomes decorated with Apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells.

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• SU-8 based microprobes for simultaneous neural depth recording and drug delivery in the brain.

  2013cited by this paper
• Translating TRAIL-receptor targeting agents to the clinic.

  2013cited by this paper
• TRAIL on trial: preclinical advances in cancer therapy.

  2013cited by this paper
• Engineering death receptor ligands for cancer therapy.

  2013cited by this paper
• SU-8 based microprobes with integrated planar electrodes for enhanced neural depth recording.

  2012cited by this paper
• A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261.

  2012cited by this paper
• Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer.

  2012cited by this paper
• TRAIL Signaling and Synergy Mechanisms Used in TRAIL-Based Combination Therapies

  2012cited by this paper
• State of art and recent developments of anti-cancer strategies based on TRAIL.

  2012cited by this paper
• A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity.

  2012cited by this paper
• Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

  2012cited by this paper
• Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis.

  2010cited by this paper
• The acid sphingomyelinase/ceramide pathway: biomedical significance and mechanisms of regulation.

  2010cited by this paper
• Exploring death receptor pathways as selective targets in cancer therapy.

  2010cited by this paper
• Cyclin-dependent kinase inhibitors as anticancer drugs.

  2010cited by this paper
• Engineering microscale cellular niches for three-dimensional multicellular co-cultures.

  2009cited by this paper
• 3-D tissue culture systems for the evaluation and optimization of nanoparticle-based drug carriers.

  2008cited by this paper
• Targeting the extrinsic apoptosis pathway in cancer.

  2008cited by this paper
• The application of low shear modeled microgravity to 3-D cell biology and tissue engineering.

  2008cited by this paper
• TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer‐specific apoptosis within a therapeutic window

  2007cited by this paper
• Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL

  2007cited by this paper
• Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.

  2007cited by this paper
• The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.

  2006cited by this paper
• Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.

  2006cited by this paper
• Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells.

  2006cited by this paper
• Ceramide mediates caspase‐independent programmed cell death

  2005cited by this paper
• Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling*

  2005cited by this paper
• Mcl-1 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Human Cholangiocarcinoma Cells

  2004cited by this paper
• Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation

  2004cited by this paper
• Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.

  2003cited by this paper
• Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.

  2001cited by this paper
• Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

  2001cited by this paper
• Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative

  2001cited by this paper
• Differential Secretion of Fas Ligand- or APO2 Ligand/TNF-Related Apoptosis-Inducing Ligand-Carrying Microvesicles During Activation-Induced Death of Human T Cells1

  2001cited by this paper
• The Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors TRAIL-R1 and TRAIL-R2 Have Distinct Cross-linking Requirements for Initiation of Apoptosis and Are Non-redundant in JNK Activation*

  2000cited by this paper
• Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles.

  1999cited by this paper
• Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

  1999cited by this paper
• A novel Arabidopsis thaliana protein protects tumor cells from tumor necrosis factor-induced apoptosis.

  1998cited by this paper
• Caspase-3 Is Required for α-Fodrin Cleavage but Dispensable for Cleavage of Other Death Substrates in Apoptosis*

  1998cited by this paper
• Ceramide signalling: regulatory role in cell proliferation, differentiation and apoptosis in human epidermis

  1997cited by this paper
• Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL*

  1997cited by this paper
• Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family*

  1996cited by this paper
• Identification and characterization of a new member of the TNF family that induces apoptosis.

  1995cited by this paper
• Apoptosis regulated by a death factor and its receptor: Fas ligand and Fas.

  1994cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper

• TRAIL-Functionalized Nanoparticles in Cancer Therapy: Molecular Mechanisms and Translational Opportunities.

  2026cites this paper
• Antineoplastic Activity of a Novel Trispecific Single-Chain Antibody Targeting the hERG1/β1 Integrin Complex and TRAIL Receptors

  2025cites this paper
• DR5 Up-Regulation Induced by Dichloroacetate Sensitizes Tumor Cells to Lipid Nanoparticles Decorated with TRAIL

  2023cites this paper
• Nano-TRAIL: a promising path to cancer therapy

  2023cites this paper
• Endogenous Soluble TRAIL Contributes to the Survival and Growth of Human Mesenchymal Stem Cells

  2021cites this paper
• Double-Edged Lipid Nanoparticles Combining Liposome-Bound TRAIL and Encapsulated Doxorubicin Showing an Extraordinary Synergistic Pro-Apoptotic Potential

  2019cites this paper
• Exosomes in sarcomas: Tiny messengers with broad implications in diagnosis, surveillance, prognosis and treatment.

  2019cites this paper
• Importance of TRAIL Molecular Anatomy in Receptor Oligomerization and Signaling. Implications for Cancer Therapy

  2019cites this paper
• High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumor effect against colon cancer

  2018influential citation
• Lipid Nanoparticles Decorated with TNF-Related Aptosis-Inducing Ligand (TRAIL) Are More Cytotoxic than Soluble Recombinant TRAIL in Sarcoma

  2018cites this paper
• NanoTRAIL‐Oncology: A Strategic Approach in Cancer Research and Therapy

  2018cites this paper
• Multiwell capillarity-based microfluidic device for the study of 3D tumour tissue-2D endothelium interactions and drug screening in co-culture models

  2017cites this paper
• Flavopiridol Strongly Sensitizes Canine Lymphoma Cells to TRAIL-induced Apoptosis.

  2017cites this paper
• High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer.

  2016cites this paper